PREVENTION OF COMPLICATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE PRESENCE OF CORONARY HEART DISEASE AND METABOLIC SYNDROME
Ivabradin has been found to significantly reduce the rate of anginal attacks and the time of silent myocardial ischemia, to optimize pulmonary ventilation-perfusion ratios, to have a positive effect on the blood pressure profile in patients with chronic obstructive pulmonary diseases in the presence of metabolic syndrome, to enhance exercise tolerance, and to reduce a risk for sudden coronary death